Search This Blog

Thursday, January 16, 2020

TG Therapeutics initiates umbralisib application in U.S.

TG Therapeutics (NASDAQ:TGTX) launches its rolling New Drug Application (NDA) in the U.S. seeking accelerated approval for umbralisib for patients with previously treated marginal zone lymphoma (MZL) and follicular lymphoma (FL). It expects to complete the filing in H1.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)